Phenotypes associated with this allele

• Allele Symbol: Abhd16a^{tm1a(EUCOMM)Wtsi}
• Allele Name: targeted mutation 1a, Wellcome Trust Sanger Institute
• Allele ID: MGI:4820220
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Abhd16a^tm1a(EUCOMM)Wtsi/Abhd16a^tm1a(EUCOMM)Wtsi	C57BL/6N-Abhd16a^tm1a(EUCOMM)Wtsi/Wtsi	MGI:6261781
hm2	Abhd16a^tm1a(EUCOMM)Wtsi/Abhd16a^tm1a(EUCOMM)Wtsi	involves: C57BL/6N * C57BL/6NTac	MGI:5817019

Genotype
MGI:6261781

hm1

• Allelic Composition: Abhd16a^{tm1a(EUCOMM)Wtsi}/Abhd16a^{tm1a(EUCOMM)Wtsi}
• Genetic Background: C57BL/6N-Abhd16a^{tm1a(EUCOMM)Wtsi}/Wtsi
• Cell Lines: EPD0605_5_A11

Data Sources

IMPC Data for Abhd16a

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

adipose tissue

decreased total body fat amount ( J:211773 )

IMPC - WTSI

growth/size/body

increased lean body mass ( J:211773 )

IMPC - WTSI

decreased body length ( J:211773 )

IMPC - WTSI

homeostasis/metabolism

decreased fasting circulating glucose level ( J:211773 )

♂

IMPC - WTSI

decreased circulating magnesium level ( J:211773 )

♂

IMPC - WTSI

mortality/aging

preweaning lethality, incomplete penetrance ( J:211773 )

IMPC - WTSI

reproductive system

male infertility ( J:211773 )

♂

IMPC - WTSI

Genotype
MGI:5817019

hm2

• Allelic Composition: Abhd16a^{tm1a(EUCOMM)Wtsi}/Abhd16a^{tm1a(EUCOMM)Wtsi}
• Genetic Background: involves: C57BL/6N * C57BL/6NTac
• Cell Lines: EPD0605_5_A11

mortality/aging

prenatal lethality, incomplete penetrance ( J:232688 )

• mice are born at a significantly lower Mendelian frequency

• however, no evidence of increased postnatal lethality is observed

growth/size/body

decreased body size ( J:232688 )

• at P1 and 10 weeks of age, mice are significantly smaller than wild-type or heterozygous littermates

• mice are ~30% smaller throughout development and life

decreased body weight ( J:232688 )

• both sexes show a significant reduction in body weight from weaning (4 weeks) to 10 weeks of age

homeostasis/metabolism

abnormal phospholipid level ( J:232688 )

• mice exhibit significant reductions in most lysophosphatidylserines (lyso-PSs) measured in brain tissue

• similar reductions in lyso-PS lipids are detected in spinal cord; however, no changes in phosphatidylserines (PSs) or other (lyso)phospholipids are noted in CNS tissues

• thioglycollate-elicited peritoneal macrophages show a ~80% reduction in cellular and secreted lyso-PSs under either basal or LPS-stimulated conditions; however, no changes in PSs, free fatty acids, eicasonoids (PGE2, PGD2, LTB4 or TXB2) or other (lyso)phospholipids are observed

• macrophages treated with inhibitors (KC01 or KC02) show no significant changes in lyso-PS secretion or other secreted and cellular lipids relative to DMSO-treated control macrophages

abnormal enzyme/coenzyme activity ( J:232688 )

• phosphatidylserine (PS) lipase activity is significantly reduced in brain and spinal cord membrane lysates relative to that in wild-type or heterozygous lysates

• thioglycollate-elicited peritoneal macrophages show greatly reduced PS lipase activity that is no longer elevated by LPS treatment, whereas LPS induces a significant increase in PS lipase activity in wild-type and heterozygous macrophages

immune system

abnormal macrophage physiology ( J:232688 )

• thioglycollate-elicited peritoneal macrophages show greatly reduced PS lipase activity that is no longer elevated by LPS treatment, whereas LPS induces a significant increase in PS lipase activity in wild-type and heterozygous macrophages

• macrophages show a ~80% reduction in cellular and secreted lyso-PSs under either basal or LPS-stimulated conditions; however, no changes in PSs, free fatty acids, eicasonoids (PGE2, PGD2, LTB4 or TXB2) or other (lyso)phospholipids are observed

• macrophages treated with inhibitors (KC01 or KC02) show no significant changes in lyso-PS secretion or other secreted and cellular lipids relative to DMSO-treated control macrophages

decreased macrophage cytokine production ( J:232688 )

• thioglycollate-elicited peritoneal macrophages show a significant reduction in LPS-induced cytokine (TNF, IL-6 and IL-1 beta) release

• basal cytokine profiles are unaffected in vehicle (PBS)-treated macrophages

• macrophages treated with inhibitors (KC01 or KC02) show no significant changes in basal or LPS-induced cytokine (IL-6 and TNF) secretion relative to DMSO-treated control macrophages

decreased interleukin-1 beta secretion ( J:232688 )

• thioglycollate-elicited peritoneal macrophages show a significant reduction in LPS-induced IL-1 beta secretion

decreased interleukin-6 secretion ( J:232688 )

• thioglycollate-elicited peritoneal macrophages show a significant reduction in LPS-induced IL-6 secretion

decreased tumor necrosis factor secretion ( J:232688 )

• thioglycollate-elicited peritoneal macrophages show a significant reduction in LPS-induced TNF secretion

hematopoietic system

abnormal macrophage physiology ( J:232688 )

• thioglycollate-elicited peritoneal macrophages show greatly reduced PS lipase activity that is no longer elevated by LPS treatment, whereas LPS induces a significant increase in PS lipase activity in wild-type and heterozygous macrophages

• macrophages show a ~80% reduction in cellular and secreted lyso-PSs under either basal or LPS-stimulated conditions; however, no changes in PSs, free fatty acids, eicasonoids (PGE2, PGD2, LTB4 or TXB2) or other (lyso)phospholipids are observed

• macrophages treated with inhibitors (KC01 or KC02) show no significant changes in lyso-PS secretion or other secreted and cellular lipids relative to DMSO-treated control macrophages

decreased macrophage cytokine production ( J:232688 )

• thioglycollate-elicited peritoneal macrophages show a significant reduction in LPS-induced cytokine (TNF, IL-6 and IL-1 beta) release

• basal cytokine profiles are unaffected in vehicle (PBS)-treated macrophages

• macrophages treated with inhibitors (KC01 or KC02) show no significant changes in basal or LPS-induced cytokine (IL-6 and TNF) secretion relative to DMSO-treated control macrophages

behavior/neurological

behavior/neurological phenotype ( J:232688 )

N • despite their smaller size, mice exhibit normal cage behavior